Wednesday, September 25, 2024
6:15 AM MT – 6:30 AM MT Registration and Breakfast
6:30 AM MT – 7:45 AM MT Symposium
Hyatt Regency Phoenix
122 N 2nd Street
Phoenix, AZ 85004
Meeting Room: Regency AB
PROGRAM FEATURES
-
- Interactive, case-based learning environment
- Downloadable Simulation Challenge
- Create your own Personalized Poster
PRESENTING FACULTY
 |
Nipa R. Shah, MD Professor & Chair Department of Community Health and Family Medicine University of Florida College of Medicine Jacksonville, FL |
 |
Muthiah Vaduganathan, MD, MPH Co-Director Center for Cardiometabolic Implementation Science Brigham and Women’s Hospital Harvard Medical School Boston, MA |
PROGRAM OVERVIEW
This innovative educational symposium shares a combination of didactic lecture and simulation case challenges tailored to enhance the clinician knowledge of SGLT2 inhibitors and GLP-1 RAs in the management of heart failure and chronic kidney disease. With a focus on evidence-based, and holistic patient care, this program strives to improve communication among multidisciplinary care team members to optimize patient care.
LEARNING OBJECTIVES
Healthcare professionals that manage patients with CKD and HF:
- Formulate strategies to promptly identify and diagnose patients with CDK or HF or those at risk for disease progression.
- Integrate evidence-based guidelines for managing CKD and HF based on the latest evidence for SGLT2i and GLP-1 RA agents and patient-specific factors.
- Discuss the clinical efficacy and tolerability profiles of approved novel and investigational agents for the treatment of CKD and HF.
Healthcare professionals that provide care for the overall management of cardio-renal-comorbid conditions:
- Implement a holistic, patient-centric care approach which streamlines communication across a multi-disciplinary care team to reduce current barriers to optimally manage patients with cardio-renal-metabolic comorbidities, including T2D, HF, and CKD
TARGET AUDIENCE
This educational activity is designed to meet the needs of healthcare providers (HCPs) who have a role in the diagnosis and treatment of patients with cardiometabolic diseases (CMDs), namely type 2 diabetes (T2DM), chronic kidney disease (CKD), and heart failure (HF). The multidisciplinary team (MDT) members for which this activity is intended include primary care physicians (PCPs; including hospitalists), endocrinologists, associated advanced practice providers (APPs; including physicians assistants and nurse practitioners), pharmacists, and certified diabetes educators.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.25 ANCC contact hours.
AAFP ACCREDITATION
This activity is acceptable for up to 1.25 Elective credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event Staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to the live event at [email protected]
